NCT03891277 (FAVORITE) is a Phase 2 clinical trial of Ferrous succinate in Vascular Cognitive Impairment, sponsored by Beijing Tiantan Hospital.

Who is sponsoring NCT03891277?

NCT03891277 is sponsored by Beijing Tiantan Hospital.

What drugs are being tested in NCT03891277?

Interventions in NCT03891277: Ferrous succinate.

What condition does NCT03891277 study?

NCT03891277 studies Vascular Cognitive Impairment, Dementia, Vascular, Iron-deficiency, Cerebral Infarction, TIA.

Is NCT03891277 still recruiting?

NCT03891277 is currently status unknown. Last updated 13 July 2020.

Last reviewed 2020-07-13 · How we verify

NCT03891277: FAVORITE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Ferrous Iron on the Prevention of Vascular Cognitive Impairment Among Patients With Cerebral Infarction/TIA (FAVORITE)

Status unknown Phase 2 Last updated 13 July 2020

What this trial tests

Phase 2 trial testing Ferrous succinate in Vascular Cognitive Impairment in 1,006 participants. Status unknown.

Timeline

1 April 2019

Primary endpoint
31 October 2021

31 December 2021

Quick facts

Lead sponsor	Beijing Tiantan Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	1,006
Start date	1 April 2019
Primary completion	31 October 2021
Estimated completion	31 December 2021
Sites	1 location across China

Drugs / interventions tested

Ferrous succinate (FERROUS SUCCINATE) — full drug profile →

Conditions studied

Vascular Cognitive Impairment — all drugs for Vascular Cognitive Impairment →
Dementia, Vascular — all drugs for Dementia, Vascular →
Iron-deficiency — all drugs for Iron-deficiency →
Cerebral Infarction — all drugs for Cerebral Infarction →

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 18 to 80, any sex, with Vascular Cognitive Impairment or Dementia, Vascular. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The prevalence of Vascular Cognitive Impairment(VCI) is high in patients after ischemic stroke or transient ischemic attack(TIA) . Effective therapy for the prevention of VCI remains limited. The primary purpose of this study is to evaluate the efficacy and safety of Ferrous iron versus placebo on the prevention of vascular cognitive impairment among patients with ischemic stroke/TIA complicated with Hemoglobin deficiency.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Efficacy and safety of Ferrous iron on the prevention of Vascular cOgnitive impaiRment among patients with cerebral Infarction/TIA (FAVORITE): rationale and design of a multicentre randomised trial.
Jia Q, Lei P, Sun L, Jia WL, et al · · 2025 · PMID 38789134 · DOI 10.1136/svn-2023-002644

Verify or expand the search:

Other trials of Ferrous succinate

Trials testing the same drug.

NCT06830941 — Iron Isomaltoside for the Treatment of Anemia in Peritoneal Dialysis Patients · Phase 4 · not yet recruiting
NCT05784870 — A Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors · Phase 3 · unknown

Other recruiting trials for Vascular Cognitive Impairment

Currently open trials in the same condition.

NCT07042633 — Mechanism of Gamma Oscillation Synchronization in the Prefrontal-hippocampal Circuit for Memory Dysfunction in Patients · recruiting
NCT05886114 — A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China · NA · recruiting
NCT04916210 — Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY · recruiting

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

NCT07341854 — Dexamethasone Palmitate for Postoperative Pain · NA · not yet recruiting
NCT07527013 — Stratified Blood Pressure Management Strategy After Endovascular Treatment for Acute Ischemic Stroke · Phase 3 · not yet recruiting
NCT07520370 — Effect of Perioperative Ulinastatin on Postoperative Stroke in Patients With Brain Tumor · NA · not yet recruiting
NCT07526987 — Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis · Phase 3 · not yet recruiting
NCT07591207 — The Efficacy and Safety of Loxoprofen Sodium Patch in Relieving Postoperative Pain After Laparoscopic Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03891277 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Tiantan Hospital
Last refreshed: 13 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03891277.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing